Literature DB >> 29405254

Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.

Y Fujisawa1, K Yoshino2, A Otsuka3, T Funakoshi4, T Fujimura5, Y Yamamoto6, H Hata7, R Tanaka1, K Yamaguchi2, Y Nonomura3, I Hirai4, S Furudate5, H Okuhira6, K Imafuku7, M Aoki8, S Matsushita8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29405254     DOI： 10.1111/bjd.16427

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  19 in total

1.  Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus.

Authors:  Łukasz Zapała; Michał Kunc; Sumit Sharma; Rafał Pęksa; Marta Popęda; Wojciech Biernat; Piotr Radziszewski
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

Review 2.  Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.

Authors:  Enrico Zelin; Carlo Alberto Maronese; Arianna Dri; Ludovica Toffoli; Nicola Di Meo; Gianluca Nazzaro; Iris Zalaudek
Journal:  J Clin Med       Date:  2022-06-11       Impact factor: 4.964

3.  Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma.

Authors:  Kenta Nakamura; Atsuko Ashida; Yukiko Kiniwa; Ryuhei Okuyama
Journal:  Arch Dermatol Res       Date:  2021-11-29       Impact factor: 3.033

4.  Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.

Authors:  Lihong Peng; Yong Wang; Fen Liu; Xiaotong Qiu; Xinwei Zhang; Chen Fang; Xiaoyin Qian; Yong Li
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

Review 5.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.

Authors:  Ming Yi; Dechao Jiao; Hanxiao Xu; Qian Liu; Weiheng Zhao; Xinwei Han; Kongming Wu
Journal:  Mol Cancer       Date:  2018-08-23       Impact factor: 27.401

6.  Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.

Authors:  Qiaoyun Tan; Shuxia Liu; Caixia Liang; Xiaohong Han; Yuankai Shi
Journal:  Thorac Cancer       Date:  2018-08-27       Impact factor: 3.500

7.  Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.

Authors:  D Viñal; L Gutierrez-Sainz; D Martinez; J A Garcia-Cuesta; J Pedregosa; J Villamayor; L Ostios; D Sanchez-Cabrero; O Higuera; A Pinto; N Rodriguez-Salas; E Espinosa; J de Castro; J Feliu
Journal:  Clin Transl Oncol       Date:  2020-11-23       Impact factor: 3.405

Review 8.  Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

Authors:  Kristina Buder-Bakhaya; Jessica C Hassel
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

9.  A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies.

Authors:  Dedong Cao; Huilin Xu; Ximing Xu; Tao Guo; Wei Ge
Journal:  Oncoimmunology       Date:  2018-08-20       Impact factor: 8.110

10.  Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort.

Authors:  Yoshihiro Ishida; Chisa Nakashima; Hiroto Kojima; Hidenori Tanaka; Taku Fujimura; Shigeto Matsushita; Yuki Yamamoto; Koji Yoshino; Yasuhiro Fujisawa; Atsushi Otsuka; Kenji Kabashima
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.